Skip to main content
Industry News
Sanofi's thrombocytopenia drug gains fast track tag

Sanofi's rilzabrutinib was granted fast track designation by the FDA as a treatment for immune thrombocytopenia based on positive results from a Phase I/II trial. The company has already initiated a late-stage trial to further evaluate rilzabrutinib.

Full Story: